American Journal of Ophthalmology
Volume 150, Issue 5 , Pages 666-673 , November 2010

Polypoidal Choroidal Vasculopathy Masquerading as Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab

  • Alexandros N. Stangos

      Affiliations

    • St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
    • Corresponding Author InformationInquiries to Alexandros N. Stangos, St. Paul's Eye Unit, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, United Kingdom
    • ,
  • Jagdeep Singh Gandhi

      Affiliations

    • St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
    • ,
  • Jayashree Nair-Sahni

      Affiliations

    • St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
    • ,
  • Heinrich Heimann

      Affiliations

    • St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
    • ,
  • Constantin J. Pournaras

      Affiliations

    • Division of Ophthalmology, Department of Clinical Neurosciences, University Hospitals of Geneva, Geneva, Switzerland
    • ,
  • Simon P. Harding

      Affiliations

    • St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
    • Ophthalmology Research Unit, School of Clinical Sciences, University of Liverpool, United Kingdom

,Accepted 26 May 2010.

References 

  1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444
  2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431
  3. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65
  4. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43–58
  5. Spaide RF, Yannuzzi LA, Slakter JS, et al. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15(2):100–110
  6. Cackett P, Wong D, Yeo I. A classification system for polypoidal choroidal vasculopathy. Retina. 2009;29(2):187–191
  7. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115(10):1837–1846
  8. Schmidt-Erfurth UM, Richard G, Augustin A, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007;85(5):486–494
  9. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566–583
  10. Hlushchuk R, Baum O, Gruber G, et al. The synergistic action of a VEGF-receptor tyrosine-kinase inhibitor and a sensitizing PDGF-receptor blocker depends upon the stage of vascular maturation. Microcirculation. 2007;14(8):813–825
  11. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92(1):70–73
  12. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: an interim 6-month report. Br J Ophthalmol. 2010;94(3):297–301
  13. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol. 2009;148(1):70–78
  14. Chan WM, Lam DS, Lai TY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111(8):1576–1584
  15. Eandi CM, Ober MD, Freund KB, et al. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina. 2007;27(7):825–831
  16. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study (Macular Photocoagulation Study Group). Arch Ophthalmol. 1991;109(9):1242–1257
  17. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report (Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group). Arch Ophthalmol. 1999;117(10):1329–1345
  18. Indocyanine green angiography. American Academy of Ophthalmology. Ophthalmology. 1998;105(8):1564–1569
  19. Stanga PE, Lim JI, Hamilton P. Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update. Ophthalmology. 2003;110(1):15–21
  20. Squirrell DM, Bacon JF, Brand CS. To investigate the prevalence of polypoidal choroidal vasculopathy in presumed age-related peripapillary subretinal neovascular membranes. Clin Experiment Ophthalmol. 2009;37(4):368–372

PII: S0002-9394(10)00402-2

doi: 10.1016/j.ajo.2010.05.035

American Journal of Ophthalmology
Volume 150, Issue 5 , Pages 666-673 , November 2010

Article Tools

* Image Usage & Resolution